[1]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-WO2015/116886,2015,A1Locationinpatent:Page/Pagecolumn291;292
[1]Tang,Siyuan;Xue,Yijie;Dengqi,Xue;Shao,Liming[EuropeanJournalofMedicinalChemistry,2023,vol.245]
1000018-10-9
1020253-85-3
105170-27-2
79491-47-7
79491-45-5
663193-84-8
10378-23-1 | Ethylenediaminetetraacetic acid tetrasodium salt dihydrate | AA008Z3V | MFCD00012460
1051919-32-4 | 3-Methyl-n-propylcyclohexanamine hydrochloride | AA008ZQM | MFCD08559399
1049036-18-1 | 2',5'-Dichlorobiphenyl-3-carboxylic acid | AA0090CV | MFCD11574811
1185300-18-8 | Methyl 2-hydroxy-4-(trifluoromethyl)pyrimidine-5-carboxylate hydrate | AA0090OK | MFCD11100556
1170404-43-9 | 2-[(4-Fluorobenzyl)sulfanyl]ethylamine, HCl | AA0090VE | MFCD09027133
103854-26-8 | (S)-2-Amino-3-(2,6-dimethylphenyl)propanoic acid | AA009137 | MFCD09842594
105462-25-7 | Risedronate Impurity C | AA0091UU | MFCD27967252
1186663-46-6 | 3-Bromo-5-fluoroindole | AA00925X | MFCD12828703
1196154-25-2 | 3-Bromo-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine-5-carboxylic acid tert-butyl ester | AA0092GS | MFCD13190301
1204810-86-5 | 3-Bromo-4-chloro-6-ethoxyquinoline | AA00932O | MFCD13192956